Swiss drugmaker shaping modern medicine
Recent reporting shows chronic inflammation is linked to aging disorders such as cancer and Alzheimer’s. Studies indicate inflammation may be a cause, not just a symptom, of broad health risks. Policy and lifestyle factors are under scrutiny as researchers push for preventative strategies.
Eli Lilly has posted another quarter of strong results driven by Mounjaro and Zepbound, lifting full-year guidance. Novo Nordisk trails in growth momentum as it works to regain share and assure investors of a clear long-term path. Foundayo’s launch adds a new dimension to Lilly’s portfolio.
Anthropic has built a wet lab in the San Francisco Bay Area to accelerate biology work, confirming a shift from in silico research to real-lab experimentation. The move comes amid warnings about AI risks and a looming IPO, with leadership stressing safety while pursuing faster drug development.
Markets have begun to stabilise as Treasuries attract inflows and AI-related debt issuance cools, amid a broader shift toward safe-haven assets. Traders are watching Fed policy as yields retreat from recent highs and tech stocks show tentative signs of recovery.
Stock markets rise as key biotech firms report favorable late-stage trial results, lifting investor sentiment in Europe and signaling potential upside for the sector. The gains come amid strong results from rinatabart sesutecan and Imdelltra combos, with investors pricing in potential longer-term adoption.